CVD Risk Reduction and Lipid Management: State of the Science in HDL Therapy

Credit Area For Credit: Register/Login     View Activity As Guest

Release Date: Aug 28, 2012          Expiration Date: Aug 28, 2013

This program has an associated Chapter Meetings; Click Here for information.

Program Description

This CME-certified program examines the importance of lipoprotein management for secondary prevention of major adverse cardiac events in post-ACS patients. Participants will learn to recognize residual risk associated with even intense statin therapy to lower LDL, as well as recognizing the limitations of current therapies to increase HDL and building an awareness of the prospects of novel therapies to increase HDL, reduce CVD risk in ACS patients, and provide primary prevention in high-risk patients.


Peter P. Toth, MD, PhD
Director of Preventive Cardiology
Sterling Rock Falls Clinic, Ltd.
Sterling, IL
Clinical Professor
University of Illinois College of Medicine
Peoria, IL
Read Biography

Michael H. Davidson, MD, FACC, FACP, FNLA
Clinical Professor
Director of Preventive Cardiology
The University of Chicago Pritzker School of Medicine
Chicago, IL
Read Biography

Target Audience

This program is intended for cardiologists and primary care physicians involved in the treatment of patients with dyslipidemia.

Educational Objectives

This program is designed to address the following IOM competencies: provide patient-centered care and employ evidence-based practice.

At the conclusion of this activity, participants should be able to demonstrate the ability to:

  • Examine the extent of residual CVD risk that continues to burden dyslipidemic ACS patients despite intensive statin treatment
  • Explain HDL metabolism and functionality in the setting of ACS
  • Compare the relative effectiveness of existing treatments to raise HDL and reduce CVD risk
  • Explain the rationale for developing CETP modulators and inhibitors to increase HDL and reduce CVD risk
  • Discuss how the modulation of complex cholesterol metabolism could have an impact on atherogenesis and improve clinical outcomes


This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education through the joint sponsorship of the Potomac Center for Medical Education and Rockpointe Corporation. The Potomac Center for Medical Education is accredited by the ACCME to provide continuing medical education for physicians.

Designation Statement

The Potomac Center for Medical Education designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 credit(s). Physicians should claim only the credit commensurate with the extent of their participation in the activity.

     For questions regarding CME credit, the post-test, or evaluation, please email

Disclosure Statement

The Potomac Center for Medical Education (PCME) adheres to the policies and guidelines, including the Standards for Commercial Support, set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME) and all other professional organizations, as applicable, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous.

All persons in a position to control the content of a continuing medical education program sponsored by the Potomac Center for Medical Education are required to disclose any relevant financial relationships with any commercial interest to PCME as well as to learners. All conflicts are identified and resolved by PCME in accordance with the Standards for Commercial Support in advance of delivery of the activity to learners. Disclosures will be made known to the participants prior to the activity.

The content of this activity was vetted by an external medical reviewer to assure objectivity and that the activity is free of commercial bias.

The faculty reported the following relevant financial relationships that they or their spouse/partner have with commercial interests:

Michael H. Davidson, MD, FACC, FACP, FNLA: Advisory Board/ Consultant: Amgen, Sanofi-Aventis, Roche, Merck; Stock Holdings: Omthera Pharmaceuticals.

Peter P. Toth, MD, PhD: Speakers Bureau: Abbott, Amgen, Amylin, AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, Kowa, Merck; Consultant: Abbott, Amgen, Amylin, AstraZeneca, Kowa, Merck

Non-faculty content contributors and/or reviewers reported the following relevant financial relationships that they or their spouse/partner have with commercial interests:

Barry Watkins, PhD; Bradley Pine; Blair St. Amand; Jay Katz; Laurie Frueh, MD: Nothing to Disclose

FDA Disclosure

The contents of some CME activities may contain discussions of non-approved or off-label uses of some agents mentioned. Please consult the prescribing information for full disclosure of approved uses.

System Requirements

In order to view this presentation, your computer must have audio capabilities (working speakers or headphones) and must have an Adobe Flash Player. The Adobe Flash Player can be downloaded here.

Instructions for Participants and Obtaining CME Credit

There is no fee for this activity. To receive credit, participants must take the pre-test, view this CME activity in its entirety, and then complete the post-test and evaluation. To complete the evaluation online, choose the best answer to each question. The estimated time for completion of this activity is 1.0 hour. To receive their certificates, participants must demonstrate mastery of the presented material via the post-test.

Jointly Sponsored By

Potomac Center for Medical Education and Rockpointe

Supported By

Supported by an independent educational grant from Genentech, Inc.

By clicking the View/Register Button you are agreeing that you have read and understood the information on this page.